Search This Blog

Tuesday, May 14, 2024

Adiposity in childhood affects risk of breast cancer by changing breast tissue composition: study

 Breast cancer is the most common cancer in women worldwide. With rates continuing to rise, there is an urgent need to identify new modifiable breast cancer risk factors. New research led by the University of Bristol suggests that higher adiposity in childhood leads to less dense breast tissue forming, which results in a reduced breast cancer risk. However, further research is needed to understand the mechanism of the overall protective effect of childhood adiposity to identify new targets for intervention and prevention.

The study, published in Nature Communications, explored the unexplained protective effect of higher  in  on  risk using Mendelian randomization, to examine the connections between body size in childhood and adulthood, puberty onset timing, breast tissue density, and breast cancer risk.

The research team looked in more detail at one of the most plausible connections—breast tissue density. Higher breast density, measured with a mammogram, is an established risk factor for breast cancer, and is known to be affected by body size.

When a mammogram shows dense breast tissue, it means there's a higher proportion of glandular or fibrous tissue compared to fatty tissue. Conversely, when breast tissue is less dense, there's more fatty tissue relative to glandular or fibrous tissue.

There is growing evidence that adiposity in childhood can lead to various adult diseases. However, in the case of breast cancer risk, observational epidemiological studies, and more recently studies that used genetic data, have shown that higher body size in childhood decreases the risk of developing this disease.

The researchers used data from  (GWAS) and Mendelian Randomization analysis. They were able to demonstrate that over 50% of the protective effect that higher childhood body size has on breast cancer risk is explained by the changes in dense breast tissue.

The research team suggest that a higher body size in childhood, around the start of puberty, leads to less dense tissue forming in the breast. The dense area is the part of the breast (glandular and fibrous ) where cancer normally develops.

Having less dense area in the breast subsequently leads to a reduced breast cancer risk in adulthood. This is the proposed mechanism by which higher childhood body size decreases breast cancer risk. However, the biological mechanism/pathway is more complex than this, and identifying smaller steps in this process using  is a part of uncovering the basis of this unexplained causal relationship.

Dr. Marina Vabistsevits from the University of Bristol's MRC Integrative Epidemiology Unit (MRC IEU) and Bristol Medical School: Population Health Sciences (PHS), and corresponding authors, said, "Studying the mechanism of childhood adiposity protective effect is important, as  in childhood cannot be considered to be a preventative measure for breast cancer.

"Investigating how this overall 'protection' works is crucial to understand the underlying mechanisms leading to and preventing cancer, as it might help identify new targets for intervention and prevention."

The study was possible thanks to a collaboration with Icahn School of Medicine at Mount Sinai and Kaiser Permanente Northern California, US, who shared invaluable mammographic density data for this project.

More information: Marina Vabistsevits et al, Mammographic density mediates the protective effect of early-life body size on breast cancer risk, Nature Communications (2024). DOI: 10.1038/s41467-024-48105-7


https://medicalxpress.com/news/2024-05-adiposity-childhood-affects-breast-cancer.html

Over Half Of Illegal Aliens In US Are Unemployed: Report

 by Eric Lundrum via American Greatness,

A new report reveals that over half of the population of illegal aliens that have come into the United States under Joe Biden’s watch are unemployed, thus creating an even greater strain on the country.

As reported by Breitbart, the report from the Center for Immigration Studies (CIS) released on Monday revealed that only 46% of illegals who came to the U.S. “in 2022 or later” were employed at the start of 2024.

“Immigration clearly adds workers to the country, but it just as clearly adds non-workers who need to be supported by the labor of others,” said CIS researchers Steven Camarota and Karen Zeigler in the report.

“This was the case in the past, it is true today, and it will surely be the case for immigrants who arrive in the future. Those who simply see immigration as a source of labor need to understand it is also a source of school children, retirees, and many other non-workers.”

The numbers in CIS’s report appear to debunk one of the most common arguments used by advocates of mass migration and open borders, who claim that illegals must be brought into the country to fill jobs that American citizens will not do.

Furthermore, CIS reported that the population of illegals in the U.S. has risen by at least 6.6 million since Joe Biden first took power in January of 2021. As of March of this year, there are over 51.6 million foreign-born illegals in the country, an increase of approximately 5.1 million since 2022. This accounts for at least 15.6% of the entire population of the United States.

“Many advocates for the unauthorized argue they should be given work permits so they can support themselves while they await a court date,” the report noted.

“Of course, others worry that this would only incentivize more illegal immigration. In 2024, a larger share of new arrivals were unauthorized relative to prior years due to the ongoing border crisis.”

CIS previously released a study debunking the Biden Administration’s attempts at claiming that it has overseen job growth in recent years, as many of the new jobs created were filled by illegals rather than American citizens; the number of employed Americans has actually decreased under Biden’s watch, falling even below pre-COVID levels.

https://www.zerohedge.com/political/over-half-illegal-aliens-us-are-unemployed-report

8,000 Women a Month Got Abortion Pills Despite Bans, Restrictions in Their States

 Though their states severely restrict abortion or place limits on having one through telehealth, about 8,000 women per month late last year were getting abortion pills by mail from states with legal protections for prescribers, a new survey finds.

Tuesday's release of the #WeCount report is the first time a number has been put on how often the medical system workaround is being used. The research was conducted for the Society of Family Planning, which supports abortion rights.

The group found that by December 2023, providers in states with the protections were prescribing pills to about 6,000 women a month in states where abortion was bannedopens in a new tab or window at all stages of pregnancy or once cardiac activity can be detected -- about 6 weeks, often before women realize they're pregnant. The prescriptions also were going to about 2,000 women a month in states where the local laws limit abortion pill prescriptions by telemedicine.

"People ... are using the various mechanisms to get pills that are out there," Drexel University law professor David Cohen said. This "is not surprising based on what we know throughout human history and across the world: People will find a way to terminate pregnancies they don't want."

Medication abortionsopens in a new tab or window typically involve a combination two drugs: mifepristone and misoprostol. The rise of these pillsopens in a new tab or window, now used for most abortions in the U.S., is one reason total abortion numbers increased even after the Supreme Court overturned Roe v. Wadeopens in a new tab or window in 2022. The survey found that total monthly abortions hovered around 90,000 in 2023 -- higher than the previous year.

After Roe was overturned, abortion bans took effect in most Republican-controlled states. Fourteen states now prohibit it with few exceptions, while three others bar it after about 6 weeks of pregnancy.

But many Democratic-controlled states went the opposite way. They've adopted laws intended to protect people in their states from investigations involving abortion-related crimes by authorities in other states. By the end of last year, five of those states -- Colorado, Massachusetts, New York, Vermont, and Washington -- had such protections in place specifically to cover abortion pill prescriptions by telemedicine.

"If a Colorado provider provides telehealth care to a patient who's in Texas, Colorado will not participate in any Texas criminal action or civil lawsuit," Cohen said. "Colorado says: 'The care that was provided in our state was legal. It follows our laws because the provider was in our state.'"

Wendy Stark, president and CEO of Planned Parenthood of Greater New York, called the shield law there "a critical win for abortion access in our state."

James Bopp Jr., general counsel for the National Right to Life Committee, said the law where the abortion takes place -- not where the prescriber is located -- should apply in pill-by-telemedicine abortions. That's the way it is with other laws, he said.

But unlike many other aspects of abortion policy, this issue hasn't been tested in court yet.

Bopp said that the only way to challenge a shield law in court would be for a prosecutor in a state with a ban to charge an out-of-state prescriber with providing an illegal abortion.

"It'll probably occur, and we'll get a legal challenge," Bopp said.

Researchers note that before the shield laws took effect, people were obtaining abortion pills from sources outside the formal medical system, but it's not clear exactly how many.

Alison Norris, MD, PhD, an epidemiologist at Ohio State University and a lead researcher on the #WeCount report, said the group is not breaking down how many pills were shipped to each state with a ban "to maintain the highest level of protection for individuals receiving that care and providers providing that care."

Rebecca Gomperts, MD, PhD, director of Aid Access, an abortion pill supplier working with U.S. providers, said having more shield laws will make the healthcare system more resilient.

"They're extremely important because they make doctors and providers ... feel safe and protected," said Gomperts, whose organization's numbers were included in the #WeCount report. "I hope what we will see in the end is that all the states that are not banning abortion will adopt shield laws."

https://www.medpagetoday.com/obgyn/abortion/110118

Donepezil Flunks Test for Chemotherapy-Related Cognitive Impairment

 

 A photo of a box of donepezil hydrochloride tablets.

The acetylcholinesterase inhibitor donepezil (Aricept) failed to improve chemotherapy-related cognitive impairment (CRCI) in breast cancer survivors, a placebo-controlled trial showed.

After 24 weeks of treatment, performance on a standardized battery of neurocognitive tests showed no significant improvement in immediate recall, the primary endpoint, compared with the placebo group. Assessments performed at 12, 24, and 36 weeks showed no significant differences on any measurements of cognitive function, reported Stephen Rapp, PhD, of Wake Forest University in Winston-Salem, North Carolina, and co-authors in the Journal of Clinical Oncologyopens in a new tab or window (JCO).

"Early preclinical and clinical studies suggested that donepezil, an acetyl cholinesterase inhibitor used effectively in patients with Alzheimer's disease, might also benefit BCS [breast cancer survivors] with CRCI," the authors stated. "Contrary to our hypothesis ... we found that among BCS who were 1-5 years post-chemotherapy and who demonstrated reported CRCI ... [treatment for] 24 weeks produced no significant benefit for memory or other cognitive domains or self-reported cognitive problems compared with a placebo."

The results raised several questions, they acknowledged. Was donepezil a reasonable treatment choice? Were the dose and timing of administration appropriate? Might certain subgroups of patients benefit from donepezil? Why did the study fail to replicate results of a pilot studyopens in a new tab or window that showed a benefit with donepezil on the same memory test?

In an interpretation of the findings, JCO associate editor Camilla Zimmermann, MD, PhD, of the University of Toronto, said donepezil is not ready for prime time to improve cognitive function after chemotherapy for cancer.

"Donepezil cannot be recommended as a treatment to improve CRCI in BCS 1-5 years after completing chemotherapy," she stated. "Further trials with a different timing of administration, different medications or medication combinations, or non-pharmacological interventions are warranted."

The FDA approved donepezil 20 years agoopens in a new tab or window for mild-to-moderate Alzheimer's disease. Multiple studies have suggested a benefit of donepezil on cognitive function in several other conditions, including vascular dementiaopens in a new tab or windowmultiple sclerosisopens in a new tab or window, and traumatic brain injuryopens in a new tab or window. In a placebo-controlled trial in patients with brain canceropens in a new tab or window treated with radiotherapy, donepezil improved performance on selected tests of neurocognitive function, but not global cognitive function.

Favorable results from the previously mentioned pilot study provided additional support for the current study, a phase III placebo-controlled trial involving breast cancer survivors with documented cognitive impairment 1-5 years after completion of chemotherapy. Investigators at 87 sites affiliated with the Wake Forest National Cancer Institute Community Oncology Research Program enrolled 276 breast cancer survivors who were at a mean of 29.6 months after completion of chemotherapy.

Patients were randomized to donepezil or placebo for 24 weeks. Objectively measured and self-reported cognitive function were assessed at baseline, 12, 24, and 36 weeks. The primary outcome was immediate recall on the Hopkins Verbal Learning Test-Revisedopens in a new tab or window (HVLT-R) at 24 weeks, and secondary outcomes were other cognitive domains, also as assessed at 24 weeks.

At 24 weeks, mean scores on the HVLT-R were 25.98 for the donepezil group and 26.50 for the placebo group. The data showed no statistically significant differences between donepezil and placebo at 12, 24, or 36 weeks for attention, executive function, verbal fluency, processing speed, or self-reported cognitive function. Neither endocrine status nor menopausal status changed the results.

Disclosures

This study was supported by a grant from the National Cancer Institute.

Rapp reported no relevant disclosures.

Zimmermann reported no relevant disclosures.

Primary Source

Journal of Clinical Oncology

Source Reference: opens in a new tab or windowRapp SR, et al "Phase III randomized, placebo-controlled clinical trial of donepezil for treatment of cognitive impairment in breast cancer survivors after adjuvant chemotherapy (WF-97116)" J Clin Oncol 2024; DOI: 10.1200/JCO.23.01100.


https://www.medpagetoday.com/hematologyoncology/breastcancer/110123

Doctor Fined for Prescribing Ivermectin for COVID

 Washington state physician Wei-Hsung Lin, MD, was fined $5,000 by the state's medical board for prescribing ivermectin during the COVID-19 pandemic.

Lin, who practices at Kadlec Regional Medical Center in Richland, Washington -- part of the Providence health system -- will also have to take continuing medical education (CME) classes on COVID and on the patient-physician relationship, according to board documents.

The Washington Medical Commission cited Lin for substandard care of five patients in 2021.

In one case, Lin prescribed ivermectin to a 69-year-old man with a long list of heart ailments, including congestive heart failure, atrial fibrillation, and coronary artery disease, as well as hypertension and type 2 diabetes.

That patient was taking an anticoagulant, which could have drug-drug interactions with ivermectin, potentially increasing the risk of internal bleeding, the board documents noted.

In addition, Lin prescribed that patient a double dose of ivermectin so he could share it with his wife, who reported having COVID symptoms. Lin couldn't prescribe the drug directly to her because only the husband was registered for the virtual visit. He prescribed the double dose so she could take half of the pills, the document stated.

Neither patient took the ivermectin after discussing it with their son.

In another instance, Lin prescribed ivermectin to a 71-year-old woman who was COVID-positive. After taking the drug for 4 days, her symptoms didn't improve, and she eventually was hospitalized with pneumonia.

Lin also prescribed ivermectin to a 37-year-old woman who said she developed symptoms after the COVID vaccine, including rash, chest pain, palpitations, weight loss, and fatigue. Lin "assessed these symptoms as concerning for persistent spike protein effects in the body leading to symptoms similar to long-term effects of COVID-19" and prescribed ivermectin, according to the board.

Finally, he prescribed ivermectin to a 67-year-old patient who simply asked for it, with no other information documented.

Going forward, Lin won't be able to prescribe ivermectin for non-FDA-approved indications, and he's not allowed to prescribe medications to patients without having an in-person or video appointment first (some of the cases mentioned above involved only phone calls).

He'll have to take 3 hours of CME on the prevention, treatment, and management of COVID, along with a CME course on the physician-patient relationship and maintaining medical records, within 6 months. He'll then have to submit two papers of at least 1,000 words each on what he learned on both topics.

Lin will also have to adhere to compliance audits and submit personal reports about compliance with the board's order. After 3 years, he can petition for an end to the oversight.

Kadlec Regional Medical Center had not responded to a MedPage Today request for comment as of press time, but told the Tri-City Herald in a statementopens in a new tab or window that it fully cooperated with the board's investigation.

"While Kadlec does not recommend or allow ivermectin for the prevention or treatment of COVID-19, we respect the rights of patients and physicians to discuss and explore all available treatment options, based on patients' unique health and medical situations," the statement said.

Four other doctors in Washington state are suing the medical boardopens in a new tab or window, challenging its position on COVID misinformation. Three of those doctors hold active licenses in the state, but are facing disciplinary action related to their alleged inappropriate care of COVID patients. A fourth previously gave up her Washington license last year.

Overall, few clinicians have been disciplined for actions taken during the COVID pandemic.

https://www.medpagetoday.com/special-reports/features/110124

Bill Gross Sells GameStop, AMC Options to Cash In on Meme Mania

 

  • “Bond King” sold calls and puts on both meme stocks Tuesday
  • Trade is a bet the shares won’t swing much in either direction

Is the erstwhile “Bond King” becoming the options king?

Bill Gross is making a habit of selling options on meme stocks, and his latest trades center on GameStop Corp. and AMC Entertainment Holdings Inc. The legendary investor said he sold calls and puts on the poster children of the meme stock mania, as the shares of both companies take off with speculators using the retail trader favorites as a way to treat the stock market as a casino.

https://www.bloomberg.com/news/articles/2024-05-14/bill-gross-sells-gamestop-amc-options-to-cash-in-on-meme-mania

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in MASH

 —With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)—

—Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval with clinical outcomes to support the potential for confirmatory or full approval—

https://www.biospace.com/article/releases/89bio-initiates-phase-3-enlighten-cirrhosis-trial-of-pegozafermin-in-metabolic-dysfunction-associated-steatohepatitis-mash-patients-with-compensated-cirrhosis/